ABIM Rheumatology Practice Questions - American Board Of Internal Medicine Rheumatology Subspecialty Certification Exam

Access More Questions

Following the 2022 FDA boxed warning update on JAK inhibitors based on the ORAL Surveillance trial, which population should generally avoid tofacitinib as first-choice therapy in RA?

Patients under 40 with no cardiovascular risk factors Patients 50 years or older with at least one cardiovascular risk factor Patients with seronegative RA regardless of age Patients on concurrent methotrexate under age 50

Correct Answer:

Patients 50 years or older with at least one cardiovascular risk factor

Access more questions from this quiz

Continue to ABIM Rheumatology Practice Questions - American Board of Internal Medicine Rheumatology Subspecialty Certification Exam for more practice questions and the full quiz experience.

Access More Questions